3-(4-Chlorobutyl)-1H-indole-5-carbonitrile Bulk Price 2026: Industrial Sourcing Guide
- Market Trend: Research-scale pricing exceeds $100/g, while industrial bulk orders significantly reduce cost per kilogram.
- Technical Spec: CAS 143612-79-7 requires strict inert storage (2-8°C) to maintain stability and industrial purity.
- Procurement: Direct manufacturing partnerships ensure consistent COA availability and optimized synthesis routes.
The pharmaceutical intermediate known as 3-(4-Chlorobutyl)-1H-indole-5-carbonitrile (CAS: 143612-79-7) represents a critical building block in the synthesis of complex serotonin modulators. As a key Vilazodone intermediate, demand for this compound is driven by the ongoing production of antidepressant therapies and allosteric IGF-1R inhibitors. For process chemists and procurement managers, understanding the disparity between catalog pricing and true manufacturing costs is essential for budget forecasting in 2026. This analysis focuses on reaction yields, scalability, and the commercial advantages of securing supply from a dedicated global manufacturer rather than relying on fragmented distribution networks.
Structurally, this indole derivative features a chlorobutyl chain attached to the 3-position and a nitrile group at the 5-position. The molecular weight is 232.71 g/mol, with a predicted boiling point of 448.1±35.0 °C. Maintaining industrial purity above 99% is crucial, as impurities in the chlorobutyl chain can complicate downstream coupling reactions. Storage protocols mandate an inert atmosphere (nitrogen or argon) at 2-8°C to prevent degradation, highlighting the need for specialized logistics during bulk transport.
Volume-Based Pricing Tiers vs Research Scale Costs
Market data indicates a steep exponential decay in price per gram as order volume increases. Research-grade suppliers typically list this compound in milligram or gram quantities, where prices can range from $23 for 1g up to $2520 for 250g packages. This pricing model reflects packaging and handling overhead rather than the actual cost of goods. For commercial-scale production, purchasing at these rates is economically unviable.
Industrial procurement shifts the focus to kilogram and multi-kilogram tiers. When evaluating the bulk price for 2026, buyers must account for the synthesis complexity. The introduction of the chlorobutyl moiety often involves precise halogenation steps that require careful temperature control to avoid poly-chlorination or indole ring degradation. Consequently, manufacturers who have optimized this synthesis route can offer competitive pricing that catalog vendors cannot match.
| Package Scale | Estimated Unit Price (USD) | Typical Application | Lead Time |
|---|---|---|---|
| 1g - 10g | $60 - $110 / g | Analytical Reference / Lab Scale | Immediate Stock |
| 100g - 500g | $30 - $50 / g | Pilot Plant / Process Development | 1-2 Weeks |
| 1kg - 5kg | Request Quote | Clinical Trial Material | 3-4 Weeks |
| 10kg+ | Request Quote | Commercial Manufacturing | 6-8 Weeks |
The table above illustrates the economic threshold where direct manufacturing becomes necessary. At the 10kg+ level, custom production runs are initiated, allowing for cost negotiation based on raw material availability and reactor capacity. Buyers seeking 3-(4-Chlorobutyl)-1H-indole-5-carbonitrile for large-scale applications should prioritize suppliers capable of validating batch consistency across tons of material.
Global Manufacturer Quotation Process for Bulk Orders
Securing a reliable supply chain requires more than just a price list; it demands technical transparency. A reputable global manufacturer will provide comprehensive documentation, including a detailed COA (Certificate of Analysis) that specifies HPLC purity, residual solvents, and heavy metal content. For this specific intermediate, the COA should confirm the absence of unreacted starting materials that could interfere with subsequent alkylation steps.
At NINGBO INNO PHARMCHEM CO.,LTD., the quotation process is designed to align with GMP standards and industrial safety protocols. When requesting a quote for bulk orders, procurement teams should specify their required purity profile and packaging preferences (e.g., fiber drums with PE liners). Unlike catalog suppliers who ship pre-packaged grams, a manufacturer can customize the packaging to suit large-scale reactor inputs, reducing waste and handling time.
Furthermore, technical support is a differentiator. Process chemists often require data on solubility (slightly soluble in chloroform and ethyl acetate) and pKa (15.93±0.30) to design downstream processes. Direct engagement with the manufacturer ensures access to this technical data, which is often omitted from standard commercial invoices. This level of support minimizes risk during scale-up and ensures that the Pharmaceutical building block integrates seamlessly into the final API synthesis.
Cost Efficiency Analysis Compared to Standard Catalog Reagents
Comparing direct manufacturing costs against standard catalog reagents reveals significant savings opportunities. Catalog vendors often act as intermediaries, adding margins to products sourced from various locations. This lack of vertical integration leads to price volatility and inconsistent quality. In contrast, a dedicated manufacturer controls the entire production lifecycle, from raw material sourcing to final quality assurance.
For example, while a research supplier might charge over $100 per gram for small quantities, a direct manufacturing partner can reduce this cost by magnitudes for bulk orders. This efficiency is achieved through optimized reaction yields and reduced solvent waste. Additionally, long-term supply agreements with a manufacturer like NINGBO INNO PHARMCHEM CO.,LTD. lock in pricing, protecting against market fluctuations anticipated in 2026.
Quality assurance is another cost factor. Impurities in intermediates can lead to failed batches in later synthesis stages, costing significantly more than the initial savings from a cheap supplier. Ensuring industrial purity from the outset reduces the need for extensive purification downstream. By verifying the synthesis route and auditing the manufacturer's facilities, companies can mitigate supply chain risks and ensure continuous production of vital medications.
In conclusion, sourcing 3-(4-Chlorobutyl)-1H-indole-5-carbonitrile requires a strategic approach that balances technical specifications with commercial viability. By moving beyond research-scale catalogs and engaging directly with capable manufacturers, pharmaceutical companies can secure the quality and pricing needed for successful commercialization.